HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Two-Drug combo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether adding MRG003 (a targeted drug) to toripalimab (an immunotherapy) before surgery can shrink tumors more than toripalimab alone in people with PD-L1-positive, locally advanced head and neck cancer. Participants receive two cycles of either the comb…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Dongguan People's Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Triple therapy aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug HH160 enters first human tests for advanced tumors
Disease control Not yet recruitingThis early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for hard-to-treat head and neck cancer: drug combo before surgery shows promise
Disease control Not yet recruitingThis study tests whether giving two drugs (becotatug vedotin and pucotenlimab) before surgery can shrink tumors in people with recurrent head and neck cancer that has stopped responding to standard treatments. About 42 adults with EGFR-positive cancer will receive 3 cycles of the…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail aims to boost head and neck cancer surgery success
Disease control Not yet recruitingThis phase II trial tests whether combining two drugs—pucotenlimab (an immunotherapy) and becotatug vedotin (a targeted chemotherapy)—given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. About 80 participants will receive eith…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New immune drug takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New mRNA shot targets Hard-to-Treat cancers in early human test
Disease control Not yet recruitingThis early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy takes aim at Hard-to-Treat salivary gland cancer
Disease control Not yet recruitingThis phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for head and neck cancer: which drug works best with radiation?
Disease control Not yet recruitingThis study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to stop head and neck cancer return
Disease control Not yet recruitingThis study tests whether adding the drug benmelstobart to standard radiotherapy and nimotuzumab can help prevent head and neck cancer from coming back after surgery. About 386 patients with intermediate-risk features will be randomly assigned to one of two groups. The main goal i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether giving radiation along with immunotherapy before surgery works better than immunotherapy alone for people with advanced head and neck cancer. About 36 adults with treatable but advanced cancer will be split into two groups. The goal is to see if the combi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Chen Chunyan • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New shorter radiation regimen aims to cut treatment time for head and neck cancer patients
Disease control Not yet recruitingThis phase II trial is testing a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this 3-week course is safe and effective at controlling the cancer while pos…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy aims to boost survival in head and neck cancer patients
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug camrelizumab to either an EGFR antibody or chemotherapy helps people with advanced head and neck cancer live longer. About 246 adults with stage III or IV head and neck cancer will receive the treatment before and after surge…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Virus and chemo combo takes on hard-to-treat head and neck cancer
Disease control Not yet recruitingThis study tests a combination of a modified virus (H101) and a targeted chemotherapy procedure (TACE) in 20 adults with head and neck cancer that has returned or spread after at least two standard treatments. The goal is to shrink tumors and boost the immune system while limitin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New triple therapy aims to wipe out head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery can shrink or eliminate tumors in people with advanced head and neck cancer. About 30 adults aged 18-70 with stage III/IVA disease who have not had prior tr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug cocktail aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests a drug called becotatug vedotin, given alone or with immune-boosting drugs (penpulimab or ivonescimab), before surgery for head and neck cancer. The goal is to see if these treatments can shrink tumors or even make them disappear completely. The study inv…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New pill targets cancer growth pathway in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a simple pill before surgery beat back head and neck cancer?
Disease control Not yet recruitingThis study tests whether taking a short course of capecitabine pills before surgery can shrink tumors and improve outcomes for people with HPV-negative head and neck cancer. About 75 adults with stage III or IVa cancer will be randomly assigned to either standard care or capecita…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New scan could sharpen detection of head and neck cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 64Cu-DOTA-ECL1i that aims to make PET scans more accurate for head and neck cancer. Researchers will enroll 90 adults with newly diagnosed or recurrent/metastatic head and neck squamous cell carcinoma. The goal is to see if this tr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Blood test could spot hidden throat cancers before symptoms start
Diagnosis Not yet recruitingThis study aims to see if a simple blood test can find HPV-related oropharyngeal cancer early in men aged 50 and older who have no symptoms. Researchers will check blood for two markers of HPV and then follow up with those who test positive to find and treat any tumors. If succes…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: UNICANCER • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Glow-in-the-dark dye could help surgeons spot cancer during head and neck surgery
Diagnosis Not yet recruitingThis early-phase trial tests a fluorescent dye called ABY-029 that may help surgeons see head and neck cancer during surgery. About 24 adults with head and neck squamous cell carcinoma will receive a tiny amount of the dye before surgery. Researchers will check safety and find th…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New radioactive antibody could light up Hard-to-Treat cancers
Diagnosis Not yet recruitingThis early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
Could a ketamine mouthwash ease radiation mouth pain?
Symptom relief Not yet recruitingThis study tests if a ketamine oral rinse can relieve pain from mouth sores (mucositis) caused by radiation therapy in head and neck cancer patients. About 62 adults receiving radiation will use the rinse and report their pain levels. The goal is to see if this simple rinse impro…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Protein shake may shield cancer patients from painful mouth sores
Symptom relief Not yet recruitingThis study tests if a daily protein drink can lower the chance of severe mouth sores caused by radiation therapy in people with head and neck cancer. About 504 adults will either get the protein supplement or a placebo drink without protein during their radiation treatment. The g…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Symptom relief Not yet recruitingThis study is for people with HPV-related oropharyngeal (throat) cancer, which often responds well to treatment. The goal is to see if lowering the radiation dose to certain areas can reduce side effects like dry mouth without hurting the chance of curing the cancer. About 132 pa…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC